CBC-Based Inflammatory Indices in Newly Diagnosed Multiple Myeloma

NCT07823959 | Not Yet Recruiting

• 1 other identifier: CBC Inflammatory Indices in MM
• Study Type: observational
• Target: 60
• Locations: 0 countries
• Sites: N/A

Brief Summary

Multiple myeloma is a type of blood cancer characterized by the abnormal growth of plasma cells in the bone marrow. Increasing evidence indicates that interactions between myeloma cells and the host immune-inflammatory response influence disease behavior and patient outcomes. Inflammatory markers calculated from routine complete blood count (CBC) tests, such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR), offer simple, inexpensive ways to assess systemic inflammation. However, how these markers correlate with baseline clinical presentation, laboratory disease burden, and tumor cell immunophenotypes remains insufficiently explored. The primary purpose of this cross-sectional study is to evaluate the association between CBC-based inflammatory indices and clinical and laboratory measures of disease severity in patients with newly diagnosed multiple myeloma prior to the start of anti-myeloma therapy. The study will also examine the relationship between these inflammatory indices and the specific immunophenotypic characteristics of neoplastic plasma cells identified via bone marrow flow cytometry. A total of 60 patients with newly diagnosed multiple myeloma presenting to Assiut University Hospital and the South Egypt Cancer Institute will be enrolled. Baseline demographic and clinical data (including CRAB manifestations and ISS/R-ISS staging), routine blood laboratory results (including albumin, beta-2 microglobulin, and LDH), bone marrow plasma cell percentages, and flow cytometric findings will be collected and analyzed.

Conditions

Multiple Myeloma

Keywords

Multiple Myeloma; Complete Blood Count; Inflammatory Indices; Neutrophil-to-Lymphocyte Ratio; Platelet-to-Lymphocyte Ratio; Lymphocyte-to-Monocyte Ratio; Systemic Immune-Inflammation Index; Flow Cytometry; Immunophenotyping

Outcome Measures

Primary Outcomes (1)

• Bone Marrow Plasma Cell Percentage

  The percentage of clonal plasma cells quantified on bone marrow aspirate/biopsy smears at diagnosis. This parameter serves as the primary objective measure of tumor burden and disease severity to evaluate its relationship with baseline complete blood count (CBC)-derived inflammatory indices (specifically the neutrophil-to-lymphocyte ratio \[NLR\]).

  Baseline

Study Arms (1)

Newly Diagnosed Multiple Myeloma Patients

Patients with newly diagnosed Multiple Myeloma evaluated prior to the initiation of anti-myeloma therapy. Baseline evaluation includes clinical assessment (demographics, CRAB features, and ISS/R-ISS staging), routine laboratory testing (serum albumin, beta-2 microglobulin, LDH, serum calcium, and renal function tests), complete blood count (CBC) to calculate inflammatory indices (NLR, LMR, PLR, SII, SIRI, PIV, HALP, and CAR), and bone marrow examination (morphological plasma cell percentage and multiparametric flow cytometry for immunophenotypic profiling of neoplastic plasma cells).

Eligibility Criteria

• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with newly diagnosed Multiple Myeloma presenting to the Clinical Pathology and Oncology Departments at Assiut University Hospital and South Egypt Cancer Institute, prior to the initiation of anti-myeloma therapy.

You may qualify if:

• Newly diagnosed Multiple Myeloma patients, evaluated prior to the initiation of anti-myeloma therapy
• Both sexes, with no age restriction

You may not qualify if:

• Prior receipt of anti-myeloma treatment
• Concurrent active malignancies or other hematological disorders
• Presence of acute or chronic inflammatory or infectious conditions that may influence systemic inflammatory indices
• Concomitant use of medications that significantly alter inflammatory or hematological parameters

Sponsors & Collaborators

• Assiut University: lead

MeSH Terms

Conditions

Multiple Myeloma

Condition Hierarchy (Ancestors)

Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident of Clinical Pathology

Study Record Dates

• First Submitted: September 11, 2026
• First Posted: September 17, 2026
• Study Start: October 1, 2026
• Primary Completion (Estimated): October 1, 2027
• Study Completion (Estimated): November 1, 2027
• Last Updated: September 17, 2026

Record last verified: 2026-09